ApprovalTrail

Approval · Notice of Compliance 25009 · 2021

APTIVUS: Notice of Compliance 25009

Issued January 15, 2021

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
25009
Date
January 15, 2021
Company
Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
Safety updates to the product monograph and migration to the 2016 product monograph format

Products in this notice

BrandDINStatus today
APTIVUSNot yet assigned—

Medicinal ingredients